IMMUNO-MYCOLOGICS, INC.

IMMY is a US-based fungal diagnostics manufacturer and distributor founded in 1979, headquartered in Norman, Oklahoma. The company develops, manufactures, and distributes innovative diagnostic tests and reagents for fungal diseases affecting immunocompromised and critically ill patients. IMMY's product portfolio spans four core diagnostic platforms: (1) Lateral Flow Assays for rapid point-of-care testing (Cryptococcal Antigen, Aspergillus Galactomannan, Coccidioides Antibody); (2) Enzyme Immunoassays for high-volume laboratory settings (Histoplasma Galactomannan, Coccidioides Antibody, Blastomyces Antibody, Cryptococcal Antigen EIA); (3) Polymerase Chain Reaction assays for molecular detection of fungal pathogens (Candida auris, Candida species, Pneumocystis jirovecii); and (4) Traditional methods including Latex Agglutination, Cleargel™ Immunodiffusion, Complement Fixation, and MycoDDR specimen processing reagents. Products target endemic mycoses (histoplasmosis, coccidioidomycosis, blastomycosis, cryptococcosis) and emerging pathogens (Candida auris) in clinical reference laboratories, hospital microbiology departments, and HIV/AIDS care settings. IMMY reports impacting over 5 million lives annually, with products distributed in over 80 countries. The company operates with 100+ dedicated employees and maintains FDA clearance for its diagnostic assays. Regulatory status and ISO certifications not explicitly stated on homepage but implied through clinical adoption and international distribution.